{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:27:37Z","timestamp":1786199257911,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1093\/jnci\/dju264","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T22:24:25Z","timestamp":1412288665000},"source":"Crossref","is-referenced-by-count":24,"title":["Effect of Oral Bisphosphonates for Osteoporosis on Development of Skeletal Metastases in Women With Breast Cancer: Results From a Pharmaco-Epidemiological Study"],"prefix":"10.1093","volume":"106","author":[{"given":"Richard","family":"Kremer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari N.","family":"Meguerditchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyne","family":"Nadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,9,23]]},"reference":[{"issue":"20 Pt 2","key":"key\n\t\t\t\t20170520220645_CIT0001","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"8","key":"key\n\t\t\t\t20170520220645_CIT0002","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"key\n\t\t\t\t20170520220645_CIT0003","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"Coleman","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"key\n\t\t\t\t20170520220645_CIT0004","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1889","journal-title":"Cancer Metastasis Rev"},{"issue":"40","key":"key\n\t\t\t\t20170520220645_CIT0005","doi-asserted-by":"crossref","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","article-title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells","volume":"272","author":"Wong","year":"1997","journal-title":"J Biol Chem"},{"issue":"6656","key":"key\n\t\t\t\t20170520220645_CIT0006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"issue":"10","key":"key\n\t\t\t\t20170520220645_CIT0007","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat Med"},{"issue":"7","key":"key\n\t\t\t\t20170520220645_CIT0008","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10585-009-9279-2","article-title":"Enhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis","volume":"26","author":"Nannuru","year":"2009","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"key\n\t\t\t\t20170520220645_CIT0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","article-title":"RANK ligand is a prerequisite for cancer-associated osteolytic lesions","volume":"198","author":"Kitazawa","year":"2002","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20170520220645_CIT0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.0105-2896.2005.00327.x","article-title":"Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system","volume":"208","author":"Tanaka","year":"2005","journal-title":"Immunol Rev"},{"issue":"1","key":"key\n\t\t\t\t20170520220645_CIT0011","first-page":"18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t20170520220645_CIT0012","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/cncr.11132","article-title":"Mechanisms of osteolytic bone metastases in breast carcinoma","volume":"97","author":"Kakonen","year":"2003","journal-title":"Cancer"},{"issue":"140","key":"key\n\t\t\t\t20170520220645_CIT0013","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"issue":"16","key":"key\n\t\t\t\t20170520220645_CIT0014","first-page":"3551","article-title":"Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice","volume":"55","author":"Sasaki","year":"1995","journal-title":"Cancer Res"},{"issue":"1","key":"key\n\t\t\t\t20170520220645_CIT0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"Fleisch","year":"2002","journal-title":"Breast Cancer Res"},{"issue":"20","key":"key\n\t\t\t\t20170520220645_CIT0016","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","article-title":"Compliance with osteoporosis medications","volume":"165","author":"Solomon","year":"2005","journal-title":"Arch Intern Med"},{"issue":"24","key":"key\n\t\t\t\t20170520220645_CIT0017","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"issue":"5","key":"key\n\t\t\t\t20170520220645_CIT0018","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"key\n\t\t\t\t20170520220645_CIT0019","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"issue":"12","key":"key\n\t\t\t\t20170520220645_CIT0020","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"key\n\t\t\t\t20170520220645_CIT0021","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170520220645_CIT0022","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"Kristensen","year":"2008","journal-title":"Acta Oncol"},{"issue":"15","key":"key\n\t\t\t\t20170520220645_CIT0023","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"issue":"28","key":"key\n\t\t\t\t20170520220645_CIT0024","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"key\n\t\t\t\t20170520220645_CIT0025","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"key\n\t\t\t\t20170520220645_CIT0026","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"key\n\t\t\t\t20170520220645_CIT0027","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"issue":"15","key":"key\n\t\t\t\t20170520220645_CIT0028","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"key\n\t\t\t\t20170520220645_CIT0029","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170520220645_CIT0030","article-title":"On Behalf of the Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)\u2019s Bisphosphonate Working Group.Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials","author":"Coleman","year":"2013","journal-title":"San Antonio Breast Cancer Symposium"},{"issue":"20 Pt 2","key":"key\n\t\t\t\t20170520220645_CIT0031","doi-asserted-by":"crossref","first-page":"6301s","DOI":"10.1158\/1078-0432.CCR-06-1211","article-title":"Oral bisphosphonates as adjuvant therapy for operable breast cancer","volume":"12","author":"Powles","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"8","key":"key\n\t\t\t\t20170520220645_CIT0032","first-page":"1133","article-title":"Waiting time for breast cancer surgery in Quebec","volume":"164","author":"Mayo","year":"2001","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t20170520220645_CIT0033","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidem"},{"issue":"9810","key":"key\n\t\t\t\t20170520220645_CIT0034","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"key\n\t\t\t\t20170520220645_CIT0035","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.3747\/co.21.1605","article-title":"Use of hormonal therapy in senior breast cancer patients treated with or without radiotherapy","volume":"21","author":"Krotneva","year":"2014","journal-title":"Curr Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170520220645_CIT0036","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-013-2636-5","article-title":"Rates and predictors of consideration for adjuvant radiotherapy among high-risk breast cancer patients: a cohort study","volume":"140","author":"Krotneva","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"key\n\t\t\t\t20170520220645_CIT0037","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2009-0852","article-title":"Effect of osteoporosis treatment on mortality: a meta-analysis","volume":"95","author":"Bolland","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key\n\t\t\t\t20170520220645_CIT0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0609.2008.01068.x","article-title":"Bisphosphonates may retrieve endothelial function in vascular diseases similar to statins\u2019 effects","volume":"81","author":"Ugur","year":"2008","journal-title":"Eur J Haematol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/106\/11\/dju264\/17313165\/dju264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T17:34:35Z","timestamp":1503509675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/dju264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,23]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,9,23]]},"published-print":{"date-parts":[[2014,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/dju264","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9,23]]}}}